Krol J - Search Results

1

Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.

McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, Krol J, Kwok JM, Polychronis A, Coombes RC, Lam EW. McGovern UB, et al. Among authors: krol j. Mol Cancer Ther. 2009 Mar;8(3):582-91. doi: 10.1158/1535-7163.MCT-08-0805. Epub 2009 Mar 10. Mol Cancer Ther. 2009. PMID: 19276163 Free article.

2

The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells.

Krol J, Francis RE, Albergaria A, Sunters A, Polychronis A, Coombes RC, Lam EW. Krol J, et al. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3169-79. doi: 10.1158/1535-7163.MCT-07-0507. Mol Cancer Ther. 2007. PMID: 18089711

3

FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.

Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, Palmieri C, Peston D, Shousha S, Yu Q, Sicinski P, Coombes RC, Lam EW. Francis RE, et al. Among authors: krol j. Int J Oncol. 2009 Jul;35(1):57-68. doi: 10.3892/ijo_00000313. Int J Oncol. 2009. PMID: 19513552 Free PMC article.

4

mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer.

Kotzsch M, Dorn J, Doetzer K, Schmalfeldt B, Krol J, Baretton G, Kiechle M, Schmitt M, Magdolen V. Kotzsch M, et al. Among authors: krol j. Biol Chem. 2011 Nov;392(11):1047-51. doi: 10.1515/BC.2011.166. Biol Chem. 2011. PMID: 21848504

5

Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.

Krol J, Sato S, Rettenberger P, Assfalg-Machleidt I, Schmitt M, Magdolen V, Magdolen U. Krol J, et al. Biol Chem. 2003 Jul;384(7):1085-96. doi: 10.1515/BC.2003.121. Biol Chem. 2003. PMID: 12956425

6

Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems.

Krol J, Kopitz C, Kirschenhofer A, Schmitt M, Magdolen U, Krüger A, Magdolen V. Krol J, et al. Biol Chem. 2003 Jul;384(7):1097-102. doi: 10.1515/BC.2003.122. Biol Chem. 2003. PMID: 12956426

7

G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.

Krol J, Paepke S, Jacobs VR, Paepke D, Euler U, Kiechle M, Harbeck N. Krol J, et al. Onkologie. 2006 Apr;29(4):171-8. doi: 10.1159/000091616. Epub 2006 Mar 29. Onkologie. 2006. PMID: 16601374 Review.

8

Primary metastatic leiomyosarcoma of the fallopian tube: a rare case report.

Jacobs VR, Zemzoum I, Kremer M, Gottschalk N, Baumgärtner AK, Krol J, Kiechle M. Jacobs VR, et al. Among authors: krol j. Onkologie. 2010;33(1-2):49-52. doi: 10.1159/000264625. Epub 2010 Jan 22. Onkologie. 2010. PMID: 20164662 Review.

9

Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer.

Harbeck N, Schmitt M, Vetter M, Krol J, Paepke D, Uhlig M, Paepke S, Jänicke F, Geurts-Moespot A, von Minckwitz G, Sweep F, Thomssen C. Harbeck N, et al. Among authors: krol j. Breast Care (Basel). 2008;3(s2):11-15. doi: 10.1159/000151734. Epub 2008 Oct 16. Breast Care (Basel). 2008. PMID: 20824008 Free PMC article. No abstract available.

10

Ex vivo detection of apoptotic trophoblast cells applying flow cytofluorometry and immunocytochemistry using M30 antibody directed to the cytokeratin 18 neo-epitope.

Krol J, Mengele K, Ottl-Mantchenko I, Welk A, Wasilewitsch I, von Steinburg SP, Schneider KT, Schmitt M. Krol J, et al. Int J Mol Med. 2005 Sep;16(3):415-20. Int J Mol Med. 2005. PMID: 16077948

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

282 results

Search Page